NewAmsterdam Pharma Co Analyst Price Targets

Wall Street analyst price targets and consensus rating for NewAmsterdam Pharma Co (NAMS).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$46Upside to Avg. PT+109.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$50→$42
Sep 8, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	Maintained	Buy	$52
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$51→$50
Jun 30, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$47→$51
Feb 19, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$41→$45
Feb 18, 2026	Needham	Serge Belanger	PT Raise	Buy	$46→$48
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$44→$47
Dec 16, 2025	Stifel	James Condulis	PT Raise	Buy	$44→$50
Dec 2, 2025	Goldman Sachs	Asad Haider	PT Raise	Neutral	$30→$37
Nov 6, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$39→$44
Nov 5, 2025	Needham	Serge Belanger	PT Raise	Buy	$40→$46
Oct 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$52
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$42→$50
Aug 25, 2025	Wells Fargo	Yanan Zhu	Initiate	Overweight	$45
Aug 7, 2025	RBC Capital	Leonid Timashev	PT Raise	Outperform	$38→$39
Jul 17, 2025	Goldman Sachs	Asad Haider	Initiate	Neutral	$27
Jun 17, 2025	Citigroup	Geoff Meacham	Initiate	Buy	$42
Jun 12, 2025	Needham	Serge Belanger	Maintained	Buy	$40
Jun 10, 2025	Stifel	James Condulis	Initiate	Buy	$44
May 8, 2025	Needham	Serge Belanger	PT Cut	Buy	$42→$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $47 to $51.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Guggenheim analyst Debjit Chattopadhyay maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $41 to $45.

Benzinga Newsdesk

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

Benzinga Insights

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

People Also Watch

People Also Watch

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Co Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PROHC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRORBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PROGuggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

PRO
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

PRO
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51

PRO
Guggenheim Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $45